AbCellera Biologics (ABCL) EBT Margin (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly EBT Margin came in at 595.75% in Q1 2026, up 65534.0% YoY from N/an in Q1 2025, and down 1270.4% on a QoQ basis from 43.47% in Q4 2025.
AbCellera Biologics (ABCL) EBT Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of EBT Margin data on file, last reported at 595.75% in Q1 2026.
- Quarterly EBT Margin rose 65534.0% year-over-year to 595.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 219.86% (up 69137.0% YoY) and the FY2025 annual result came in at 236.39%, up 45863.0% from the prior year.
- EBT Margin declined to 595.75% in Q1 2026, from 43.47% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 72.91% in Q1 2022 to a low of 1251.1% in Q1 2025.
- A 5-year average of 458.1% and a median of 429.45% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 88383 bps in 2025, down 82165 bps in 2025.
- Tracing ABCL's EBT Margin over 5 years: stood at 145.8% in 2022, then tumbled by 263 bps to 529.49% in 2023, then sank by 75 bps to 927.31% in 2024, then jumped by 95 bps to 43.47% in 2025, then sank by 1270 bps to 595.75% in 2026.
- The last three EBT Margin figures came in at 595.75% (Q1 2026), 43.47% (Q4 2025), and 767.93% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -1,455.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,455.93% |
| Mar 31, 2026 | -595.75% |
| Dec 31, 2025 | -43.47% |
| Sep 30, 2025 | -767.93% |
| Jun 30, 2025 | -212.74% |
| Mar 31, 2025 | -1,251.10% |
| Dec 31, 2024 | -927.31% |
| Sep 30, 2024 | -962.53% |
| Jun 30, 2024 | -658.02% |
| Mar 31, 2024 | -429.45% |
| Dec 31, 2023 | -529.49% |
| Sep 30, 2023 | -595.18% |
| Jun 30, 2023 | -377.92% |
| Mar 31, 2023 | -394.91% |
| Dec 31, 2022 | -145.80% |
| Sep 30, 2022 | 45.95% |
| Jun 30, 2022 | -15.00% |
| Mar 31, 2022 | 72.91% |
| Dec 31, 2021 | 60.80% |
| Sep 30, 2021 | -453.38% |